For patients with treatment-resistant epilepsy, advanced leukemia, chronic insomnia, or the long tail of conditions where cannabinoid medicine has been promised more often than proven, the gap between anecdote and evidence is the gap that matters. A Herzliya-based research outfit founded out of the Technion is trying to close that gap one molecule at a time, and as of early November it has a deeper-pocketed partner to help carry the work toward the clinic.
Cannasoul R&D Ltd., the cannabis research and analytics company founded by Prof. Dedi Meiri of the Technion, Israel Institute of Technology, announced on November 3 that InterCure Ltd. had signed a definitive share purchase agreement and a collaboration agreement covering an initial 28% ownership stake with an option to increase that position to 51% [GlobeNewswire, Nov 2025]. Prof. Meiri, who serves as Chairman and Chief Scientific Officer of Cannasoul [Markets Insider, Apr 2020], is set to chair a new Scientific Advisory Board at InterCure as part of the deal [Cannabis Business Times, Nov 2025]. Financial terms of the 2025 transaction were not disclosed.
The bet
Cannasoul's wedge is analytical depth. The company says its proprietary profiling methods can characterize more than 100 cannabinoids and more than 100 terpenes and flavonoids per cannabis strain, which it describes as the broadest available coverage in the field [Neoteryx]. That matters because the therapeutic conversation around cannabis has been bottlenecked for years by the fact that most clinical work focuses on two molecules, THC and CBD, while the plant produces hundreds of bioactive compounds whose individual and combinatorial effects remain poorly mapped. Cannasoul's stated focus is the research, development, and commercialization of evidence-based cannabis therapeutics [GlobeNewswire, Nov 2025], with active programs in disease areas including leukemia, epilepsy, sleep disorders, and breast cancer [Benzinga, Nov 2023] [Professionally Cannabis Podcast]. The company has also pursued a terpene formulation aimed at modulating the cytokine storm seen in viral infections, in collaboration with Eybna [Markets Insider, Apr 2020].
As context for readers outside oncology and neurology: standard of care today for refractory pediatric epilepsy syndromes such as Dravet and Lennox-Gastaut already includes one FDA-approved cannabidiol product (Epidiolex), layered onto traditional antiepileptics. For acute myeloid leukemia and most breast cancer subtypes, cannabinoids play no role in front-line therapy, which remains chemotherapy, targeted agents, immunotherapy, and in some settings stem cell transplant. Sleep disorders are still managed largely with cognitive behavioral therapy for insomnia and a narrow set of approved hypnotics. Any cannabinoid program aiming at these indications is competing against entrenched, evidence-backed regimens, and would need controlled trials to earn a seat at the table.
Why the InterCure deal could matter
InterCure is one of the larger pharmaceutical-grade cannabis operators tied into the Israeli medical system, and the company has signaled it expects the partnership to feed both clinical research and commercial product development [Cannabis Business Times, Nov 2025]. For an academic spinout, that kind of strategic relationship solves two chronic problems at once: access to GMP-quality plant material at scale, and a commercial partner willing to underwrite the long arc from preclinical work to regulated product. The structure of the deal, with InterCure able to move from 28% to 51% [Investing.com, Nov 2025], suggests a staged commitment that rewards execution on agreed milestones rather than a one-shot bet.
The regulatory weather is also shifting. U.S. discussion of rescheduling cannabis from Schedule I to Schedule III, if it advances, would meaningfully change the calculus for clinical research in the United States by easing some of the DEA-imposed friction that has slowed academic trials for two decades. Cannasoul's research-first posture, anchored in a Technion lab rather than a dispensary brand, is the kind of asset that becomes more valuable in a world where regulators and payers begin to demand pharmaceutical-grade evidence rather than consumer testimonials.
The team and the money in
Prof. Meiri's lab at the Technion is one of the more cited cannabis pharmacology groups internationally [GlobeNewswire, Nov 2025], and Cannasoul is co-founded with the Technion Research & Development Foundation, the university's commercialization arm [StreetInsider, Nov 2023]. That academic anchoring is the company's clearest credential. On the capital side, before the 2025 InterCure transaction, Synaptogenix acquired a 25% minority stake in Cannasoul Analytics for $4 million in November 2023 [MarketScreener, Nov 2023], with a parallel partnership to support research into psilocybin therapeutics [PRNewswire]. The company's investor roster therefore now spans a U.S.-listed neuroscience biotech and an Israeli cannabis pharmaceutical operator, which is an unusually focused cap table for a company at this stage.
Synaptogenix stake (2023) | 25 | % ownership
InterCure initial stake (2025) | 28 | % ownership
InterCure option ceiling | 51 | % ownership
The honest counterfactual
The bear case is straightforward and worth stating plainly. Cannabinoid therapeutics have a long history of preclinical promise that has not consistently translated into approved medicines, and a research company whose commercial fate is increasingly tied to a single strategic partner inherits that partner's exposure to a volatile cannabis market [QuiverQuant, Nov 2025]. None of the disease-area programs cited here, leukemia, epilepsy, breast cancer, sleep, or the antiviral terpene work, has been reported in this evidence set as having reached pivotal clinical trials, and no peer-reviewed efficacy data is cited above. The bull answer, supported by the structure of the InterCure deal, is that Cannasoul is being bought into precisely because the next decade of cannabis medicine will be decided by groups with rigorous analytical chemistry and academic provenance rather than by brand-led operators, and Prof. Meiri's lab is one of the few that fits that description [GlobeNewswire, Nov 2025].
What to watch
Over the next twelve months, the milestones that will tell the story are concrete: whether InterCure exercises its option to move past 28% toward majority ownership [Investing.com, Nov 2025], whether the Scientific Advisory Board chaired by Prof. Meiri produces a published research roadmap, and whether any of the named programs (leukemia, epilepsy, sleep, the Eybna terpene collaboration) advances into a registered clinical trial with a defined patient population and endpoint. Movement on U.S. rescheduling would be a tailwind that matters more to Cannasoul than to most of its peers, because the company's value sits in research output rather than retail shelf space.
The disease states are real. The patients are waiting. The question Cannasoul now has the resources to answer is whether the chemistry it has spent years cataloguing can be turned into something a regulator will approve and a clinician will prescribe.